3995 results about "Magnesium stearate" patented technology

The invention discloses a medicinal preparation rizatriptan benzoate capsule for treating migraine and a preparation method thereof. Every 10000 capsules are prepared from the following formulation constituents: 29-250g of rizatriptan benzoate, 20-400g of microcrystalline cellulose, 220-1100g of starch, 100-400ml of 10-20% polyvinyl pyrrolidone ethanol solution and 4-30g of magnesium stearate. The invention also provides a preparation method of the rizatriptan benzoate capsule. The capsule of the invention covers the foreign taste of the main medicine; release and absorption of the medicine are accelerated; medical particles in the capsule are not punched or molten, thereby overcoming some defects of tablets; after the capsule is taken orally, the medicine is directly dispersed in the gastrointestinal fluid and is moistened by the gastrointestinal fluid, thus the effective surface area is large; and the medicine has higher dissolving rate in the gastrointestinal fluid, can be better absorbed and has high bioavailability.

The invention relates to a xanthophylls microcapsule and a preparation method thereof. The core material of the microcapsule is xanthophylls and the wall material is natural macromolecule chitosan or glutin, gum acacia and antioxidant. The technique has the following steps: the xanthophylls is dissolved in an organic solvent, which is added into a gum acacia solution containing emulsifier and antioxidant for uniform emulsion; the well emulsified gum acacia is added into the chitosan or glutin solution for being condensed into capsules, and the capsules are processed with magnesium stearate after solidification; the microcapsules with excellent dispersivity are obtained after drying. The microcapsule prepared by the technique has the grain diameter of 1-200 Mum. The preparation technique has simple process, mild preparation condition and easy popularization; the microcapsule prepared has good dispersivity and high stability and is suitable for industries such as food, health care products, feed, etc.

The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. One of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.

The invention provides a metal surface oil and rust removal agent, and belongs to the technical field of cleaning agents. The metal surface oil and rust removal agent comprises the following components by weight: 2 to 4 parts of hydrochloric acid, 5 to 10 parts of phosphoric acid, 3 to 6 parts of oxalic acid, 3 to 5 parts of glacial acetic acid, 2 to 4 parts of citric acid, 3 to 4 parts of polyvinyl alcohol, 1 to 2 parts of hexamethylene tetramine, 2 to 3 parts of ethylene oxide, 1 to 2 parts of glyoxal, 2 to 3 parts of magnesium stearate, 2 to 4 parts of glycerol, 2 to 4 parts of thiourea, 2 to 4 parts of ammonium molybdate, 1 to 2 parts of polyaspartic acid, 2 to 4 parts of EDTA-Na2, 1 to 2 parts of ethylene diamine tetra sodium, 1 to 3 parts of poly maleic acid sodium, 2 to 3 parts of HEDPA, 2 to 6 parts of surface active agent and 70 to 100 parts of water. The metal surface oil and rust removal agent is convenient to use, and removes light rust for about 2 minutes and heavy rust for 6 to 7 minutes, and the oil removal rate can reach more than 97%.

The invention discloses a preparation method for highly effective compound dietary cellulose. The method of the invention is characterized in that: the highly effective compound dietary cellulose is prepared with the following materials, insoluble dietary fiber, water-soluble dietary fiber, vitamin C and lactic acid bacteria powder, in definite proportions. The product of the invention is the highly effective compound dietary cellulose which is provided with dual characteristics of insoluble dietary fiber and water-soluble dietary fiber and the dosage form of the product can be capsules or granules. The long-term taking of the product of the invention can ensure obvious curative effects on high blood pressure, high blood fat, high cholesterol, diabetes, obesity, constipation, gastro-intestinal diseases, etc. If being added with different materials such as microcrystalline celluloses, magnesium stearate, maltodextrin, citric acid, sodium bicarbonate and PEG6000, according to different preparation forms, the product can also be prepared into tablets, chewable tablets and effervescent tablets. The highly effective compound dietary cellulose of the invention has simple, scientific and reasonable prescription, simple technology and stable quality, and is easy to be produced in large scale, thus being a safe and green health-care food product.

The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability.

The invention discloses acomposite potassium peroxymonosulfate disinfection tablet which comprises 10.0-70.0 parts by weight of potassium monopersulfate, 1.0-65.0 parts by weight of fillers, 1.0-20.0 parts by weight of adhesives and 0.01-10.0 parts by weight of lubricant, wherein the fillers is formed by one or more then one of sodium sulfate, sodium chloride, potassium chloride, sodium carbonate, sodium bicarbonate, phosphate, inorganic acid, organic acid, starch, dextrin, glucose, solid emulsifier, xylitol and a metal ion complexing agent, the adhesives comprise cellulose, polyvinylpyrrolidone and gelatin; the lubricant is formed by one or more than one of magnesium stearate, talcum powder, micro-powder silica gel, sodium benzoate and polyethylene glycol; in addition, sodium percarbonate, calcium percarbonate, sodium perborate or calcium peroxide 1-2 are added. The invention is convenient to use, has the advantages of quick disintegration and dissolution, can significantly increase the effect of the disinfection tablet and can adjust pH value.

The preparation method of ginkgo leaf slow-released tablet mainly for curing cerebrovascular disease includes the following steps: 1. preparing gingko leaf extract; and 2. preparing slow-released tablet: using gingko leaf extract 120 portions, hydroxypropyl methyl cellulose 80-100 portions, lactose 50-80 portions and starch 30-80 portions, mixing them uniformly, adding anhydrous ethanol 0.8-1.2 portions to make granulation, then adding magnesium stearate 2-5 portions, uniformly mixing them and tabletting to obtain said invented product.

A dispersing table of amlodipine benzosulfonate for treating hypertension is proportionally prepared from amlodipine benzosulfonate, microcrystalline cellulose, anhydrous lactose, carboxymethyl starch sodium, micropowdered silica gel, and magnesium stearate.

Addition of magnesium stearate to a powder formulation for inhalation comprising carrier particles and an active ingredient bearing a group susceptible to hydrolysis is useful for inhibiting or reducing the chemical degradation of the active ingredient.

The invention discloses a chitosan oligosaccharide capsule; chitosan oligosaccharide with 2000-10000 of molecular weight, radix salviae miltiorrhizae extract, pueraria root extract, obtuseleaf senna seed extract and schisandra extract are used as main materials; starch and magnesium stearate are taken as auxiliary raw materials; the weight components of the formula of the chitosan oligosaccharide capsule include the chitosan oligosaccharide, the radix salviae miltiorrhizae extract, the pueraria root extract, obtuseleaf senna seed extract, schisandra extract, the starch and the magnesium stearate; the production process of the capsule is that: sieving, weighting, mixing, capsule filling, polishing, screening, inside and outside package, warehouse-in inspection are carried out to prepare the health-care product. The chitosan oligosaccharide capsule has the advantages that the main composition of the capsule comprises the chitosan oligosaccharide, general flavone and total anthraquinone; the capsule is taken orally two times one day, 3 granules each time, and the capsule has auxiliary protection function to the chemical liver damage.

The invention provides a Dendrobium candidum polysaccharide buccal tablet comprising the following components by weight portions: 30-100 portions of Dendrobium candidum polysaccharide, 380-420 portions of xylithol as a carrier, 300-340 portions of aspartame, 0.5-1.5 portions of menthol, 0.5-1.5 portions of aerosol and 4-6 portions of magnesium stearate; and the invention also provides a preparingmethod of the Dendrobium candidum polysaccharide buccal tablet, comprising the following steps: taking the Dendrobium candidum polysaccharide as raw material, adding auxiliary material, uniformly mixing according a certain proportion, and tabletting and shaping to obtain the product. The Dendrobium candidum polysaccharide is easy to be taken, and fresh and cool in mouthfeel, can be directly absorbed through oral mucosa, avoids loss generated when nutrients are absorbed by organs such as human gastrointestine, liver and the like, improves the absorption utilization ratio of nutrients in Dendrobium candidum polysaccharide, and has important significance to clinical treatment and the prevention and development of health care products.

The invention discloses benzene sulfonic acid levo-amlodipine pills and a preparation method thereof. On the basis of 1000 pills, the benzene sulfonic acid levo-amlodipine pill comprises 1-10g of benzene sulfonic acid levo-amlodipine, preferably 2.5g; 50-100g of lactose, preferably 67-87g and most preferably 80g; 5-55g of low-substituted hydroxy propyl cellulose, preferably 20-40g and particularly preferred 30g; 2-20g of crosslinked polyethylene ketopyrrolidine, preferably 5g; and 0.5-2.5g of magnesium stearate, preferably 1.5g. The benzene sulfonic acid levo-amlodipine pills have more than 95 percent of dissolution rate and good production stability.

The invention relates to a levamlodipine besylate tablet, a preparation process thereof and a control method for relevant materials. Each 1000 levamlodipine besylate tablets provided by the invention comprise the following compositions: 2.5g of levamlodipine besylate (measured in besylate), 30 to 50g of lactose (as a filler), 20 to 40g of beta-cyclodextrin (as an inclusion agent), 25 to 45g of microcrystalline cellulose (as a disintegrating agent), 5 to 15g of cross-linked polyvinylpyrrolidone (as a disintegrating agent), 1 to 2g of magnesium stearate (as lubricant), and 50 to 80g of 2.5% HPMC (hydroxypropyl methylcellulose) and 50% ethanol (as an adhesive). The levamlodipine besylate tablet provided by the invention has the advantages of making multi-item improvements on the properties of the levamlodipine besylate, increasing the solubility and apparent dissolution rate of the tablet, improving the stability of the tablet, reducing the excitability of the tablet, significantly reducing the limit of the relevant material, and having better clinical treatment effect, so that the blood pressure lowering of the patient with hypertension is more stable.

The invention belongs to the field of traditional Chinese medicines or healthcare foods, relates to a dendrobium preparation, and in particular relates to dendrobium buccal tablets. The formula of the dendrobium buccal tablets is composed of dendrobium ultra-fine powder, mannitol, white granulated sugar powder, magnesium stearate, aerosol, citric acid, borneol/menthol, mint oil and mint essence, wherein under the formula aforementioned, wet granulation is performed, and then tabletting is performed to prepare the buccal tablets; and the dendrobium buccal tablets prepared by the formula are high in bioavailability and good in taste. Additionally, the invention further discloses a preparation process for dendrobium ultra-fine powder. The preparation process specifically comprises the following steps of: peeling the cleaned fresh dendrobium bars; drying and slicing to achieve a thickness of not greater than 1 mm; and performing drying treatment at 50-60 DEG C to cause the water content to be 2-3%, and crushing for 10-30 minutes by an ultra-fine crusher, so as to obtain the dendrobium ultra-fine powder. According to the process, the loss rate of the precious medicine of dendrobium is further reduced by optimizing the slice thickness and omitting the step of processing crude powder.

The invention relates to a lansoprazole crystalline compound. An X-ray powder diffraction pattern represented by a diffraction angle of 2 theta +/- 0.2 DEG displays feature diffraction peaks at the positions of 5.8 DEG, 7.5 DEG, 9.1 DEG, 11.8 DEG, 12.1 DEG, 12.8 DEG, 13.3 DEG, 15.6 DEG, 16.7 DEG, 18.3 DEG, 20.4 DEG, 25.7 DEG, 26.8 DEG and 31.5 DEG. The invention also relates to a lansoprazole enteric capsule containing the lansoprazole crystalline compound. The lansoprazole enteric capsule comprises 20 to 60 parts of l crystalline compound, 90 to 140 parts of microcrystalline cellulose, 1.5 to 3.5 parts of disodium hydrogen phosphate, 2 to 5 parts of anhydrous sodium sulphite, 1 to 10 parts of crospovidone, 0.8 to 4.2 parts of lauryl sodium sulfate, 2 to 8 parts of povidone K30 and 1 to 3 parts of magnesium stearate.

The aim of the invention is to improve the moisture resistance of dry powder formulations for inhalation which contain a pharmaceutically ineffective carrier of not-inhalable particle size and a finely divided pharmaceutically active compound of inhalable particle size and to also improve the storage stability of said formulations. To this end, magnesium stearate is used in said formulations. On of the features of the inventive dry powder is that a high fine particle dosage or fine particle fraction can be maintained also under relatively extreme temperature and humidity conditions.

The invention provides an ultrafine moringa oleifera powder compressed buccal tablet, and a preparation method thereof. The ultrafine moringa oleifera powder compressed buccal tablet is characterized in that the ultrafine moringa oleifera powder compressed buccal tablet includes the following components by weight percent: 40 to 60 percent of moringa oleifera, 10 to 40 percent of ultrafine maca powders, 5 to 20 percent of maltodextrin, 5 to 50 percent of fructose, and 0.5 to 1 percent of magnesium stearate. The preparation method for the ultrafine moringa oleifera powder compressed buccal tablet is characterized in that the preparation method includes the following steps: (1) freeze drying: fresh moringa oleifera leaves are placed in a freeze drying machine for freeze drying and moisture removal, so that the water content is kept between 3 percent and 6 percent; (2) ultrafine grinding: the moringa oleifera leaves after freeze drying undergo ultrafine grinding in an ultrafine grinder at the normal temperature; (3) compounding: the moringa oleifera, the ultrafine maca powders, the maltodextrin, the fructose and the magnesium stearate are poured into a mixing machine to be sufficiently and uniformly mixed; (4) tabletting: the mixed materials are tabletted through a tablet press. The buccal tablet provided by the invention can supplement daily values for calcium, protein, vitamins, potassium, iron and other elements for human bodies.

The invention discloses an ecological organic compound fertilizer which is characterized by being prepared from the following raw materials in parts by weight: 40-45 parts of straw powder, 12-14 parts of ramulus mori powder, 20-23 parts of silkworm excrement, 12-14 parts of peanut shells, 5-7 parts of bock greenbrier rhizome, 34-38 parts of urea, 20-24 parts of calcium superphosphate, 18-20 parts of dipotassium phosphate, 14-17 parts of ammonium nitrate, 12-16 parts of humic acid, 2-3 parts of lime, 2-3 parts of hydroxypropyl methyl cellulose, 1-2 parts of magnesium stearate, 3-4 parts of an EM (Effective Microorganisms) fungicide, 4-6 parts of a developing agent and a proper amount of water. The fertilizer disclosed by the invention contains more and reasonable nutritional ingredients and can satisfy all fertilizers required by plants in the growing period, the fertilizer is excellent in slow release performance, has a long-term effective effect, supplements trace elements of soil, improves the yield and quality of the plants, is beneficial to human health and further improves the soil fertility at the same time. Meanwhile, the efficacy of the fertilizer can be further exerted to the maximum extent, and the application amount of the fertilizer is reduced, resources are saved, and the environment is protected. The fertilizer has economical and environmental benefits.

This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.